A New Nordisk, a Danish pharmaceutical company, has achieved the title of most valuable company in Europe. Thus, it ends the two and a half year reign of the French luxury group LVMH, responsible for brands such as Louis Vuitton and Sephora.
The pharmaceutical company had already achieved second place on the continent, surpassing Nestlé and becoming increasingly closer to first place.
see more
Unprecedented: multimarket fund returns to the black after almost a year
Is this the end of 'gatonet'? Anatel strengthens anti-piracy with…
However, the increase in the company's name and the advancement of its position to reach the first place of European companies came in the year 2023.
This brought the company to a new level on the European scene and demonstrated its value. Let's understand a little more about the details of overcoming first place and how the organization reached the top of Europe.
Currently, the pharmaceutical company has an impressive market value, reaching the US$425 billion mark.
This remarkable rise is largely due to the success of Ozempic, a highly effective medication in diabetes treatment and weight loss efforts.
In addition, Novo Nordisk also offers the Wegovy, a drug equally popular among Hollywood celebrities, known for its effectiveness in weight reduction. These remedies were responsible for propelling the brand to first place on the European stock market.
The effectiveness of these injectable medications triggered what can be described as a true “gold rush” in the pharmaceutical industry.
Since the August 8 announcement that a large study proved Wegovy's cardiovascular benefits, the company's shares have risen approximately 17%.
(Image: disclosure)
Novo Nordisk was created in 1923 and is headquartered in the capital of Denmark, Copenhagen. Its activities include branches all over the world and its products are sold in around 170 countries.
Thus, the company demonstrated its capacity for innovation and leadership in the production of medicines that address critical health issues such as diabetes and obesity.
Its successful trajectory, marked by scientific advances and market achievements, now places it as the most valuable company in Europe.
The points achieved by the organization strengthen its image and consolidate its prominent position in the global pharmaceutical industry.
With Ozempic and Wegovy, Novo Nordisk continues to transform lives and shape the future of healthcare on a global scale.
Therefore, the organization has been growing more and more and must continue to follow the path of success that it has demonstrated to the public. Thus, it is a strong competitor in the European market and makes its competitors increasingly fight for space and results.
